#United States #San Diego #biopharmaceuticals #Investor Conferences #Neurocrine Biosciences

Neurocrine Biosciences to Present at Investor Conferences

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), an innovative biopharmaceutical company based in San Diego, has announced its participation in a series of important investor conferences this September. The company aims to showcase its commitment to developing life-changing treatments for patients with neurological and psychiatric disorders. Through these conferences, Neurocrine's executives will engage with investors and share insights about the company’s latest advancements and pipeline developments.

The upcoming conferences include:

• - Wells Fargo 21st Annual Healthcare Conference: Scheduled for September 9, 2026, where a fireside chat will take place at 12:45 PM ET in Boston.
• - Cantor Global Healthcare Conference 2026: Set for September 10, 2026, featuring a fireside chat at 8:35 AM ET in New York.
• - Morgan Stanley 24th Annual Global Healthcare Conference: This event occurs on September 15, 2026, with a fireside chat at 10:45 AM ET, also in New York.

Investors interested in these presentations can access live webcasts on Neurocrine Biosciences' official website under the Investors section at www.neurocrine.com. For those unable to attend live, a replay of the webcasts will be available approximately one hour after the conclusion of each event and will be archived for about a month.

About Neurocrine Biosciences

Neurocrine Biosciences is dedicated to addressing significant unmet needs in the healthcare sector. With over three decades of expertise in neuroscience, the company has established a reputation for pioneering research and development in the field. They focus on a variety of conditions including neurological, psychiatric, endocrine, and immunological disorders.

Their current portfolio includes FDA-approved treatments for serious conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, and disorders linked to Prader-Willi syndrome, among others. Neurocrine also has ongoing clinical developments with numerous compounds in various phases aimed at generating innovative therapies that help improve the quality of life for their patients.

Innovation and Commitment

Neurocrine’s mission extends beyond mere treatment; it strives to relieve suffering for individuals facing debilitating diseases. Their approach integrates unique insights into how brain and body systems interact, driving the relentless pursuit of new therapeutics.

The company's vision is reflected in its tagline: “You deserve brave science,” which underscores their commitment to bold and innovative research that aims to enhance patient care and outcomes.

For additional updates and information, stakeholders can follow Neurocrine Biosciences on various social media platforms, including LinkedIn, X, Facebook, and YouTube.

Conclusion

The forthcoming investor conferences mark a significant opportunity for Neurocrine Biosciences to demonstrate their progress and vision in the biopharmaceutical landscape. As they gear up for these events, the industry eagerly anticipates insights that may shape the future of healthcare and therapeutic approaches in addressing complex health challenges.